



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|--|--|--|---|--------------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S) | | | | ATTY. DOCKET NO. R0150C-REG | SERIAL NO. 10/717,260 |
| | | | | FIRST NAMED INVENTOR Joseph Armstrong Martin | |
| | | | | FILING DATE November 19, 2003 | ART UNIT unknown |
| Page 1 of 2 | | | | | |

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|-----------------------|----------------------|--------------------------------------|---|---|---|
| Examiner Initials * | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number | Kind Code ² (if known) | | | |
| M.C.H. | A1 | 3,998,807 | | John G. Moffatt | 12-21-1976 | |
| | A2 | 4,957,924 | | Lilia M. Beauchamp | 09-18-1990 | |
| | A3 | 5,216,142 | | Horrobin, et al. | 06-01-1993 | |
| M.C.H. | A4 | 6,184,376 | | Leanna, et al. | 02-06-2001 | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ₆ |
|--------------------|-----------------------|-------------------------|---------------------|--------------------------------------|---|---|---|----------------|
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| M.C.H. | B1 | WO | 02/100415 | A2 | F. Hoffmann-La Roche (CH) | 12-19-2002 | | |
| | B2 | WO | 01/45509 | A1 | ICN Pharmaceuticals, (US) | 06-28-2001 | | |
| | B3 | WO | 01/68034 | A2 | ICN Pharmaceuticals (US) | 09-20-2001 | | |
| | B4 | WO | 01/90121 | A2 | Novirio Pharmaceuticals, Ltd. Et al. (US),(IT) | 11-29-2001 | | |
| | B5 | WO | 00/23454 | A1 | Schering Corp. (US) | 04-27-2000 | | |
| | B6 | WO | 94/22887 | A1 | Norsk Hydro A.S. (NO) | 10-13-1994 | | |
| | B7 | WO | 94/24134 | A1 | Hoechst AG (DE) | 10-27-1994 | | |
| | B8 | WO | 93/07163 | A1 | Norsk Hydro A.S. (NO) | 04-15-1993 | | |
| | B9 | EP | 0 375 329 | B1 | The Wellcome Foundation Ltd.(GB) | 06-27-1990 | | |
| M.C.H. | B10 | EP | 0 343 133 | B1 | Medivir Aktiebolag (SE) | 11-23-1989 | | |

| | | | |
|--------------------|-----------|-----------------|---------|
| Examiner Signature | <i>MR</i> | Date Considered | 8/17/04 |
|--------------------|-----------|-----------------|---------|

| | | | |
|---|--|---|--------------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S) | | ATTY. DOCKET NO. R0150C-REG | SERIAL NO. 10/717,260 |
| | | FIRST NAMED INVENTOR Joseph Armstrong Martin | |
| Page 2 of 2 | | FILING DATE November 19, 2003 | ART UNIT unknown |

THER PRIORITY ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|---|----------------|
| M.C.H | C1 | BALIMANE, et al., "Direct Evidence for Peptide Transporter (PEPT1)-Mediated Uptake of a Nonpeptide Prodrug, Valacyclovir," Biochemical and Biophysical Research Communications, (1998) pp. 246-251, vol. 250, Article No. RC989298 | |
| | C2 | BEAUCHAMP, et al., "Amino Acid Ester Prodrugs of Acyclovir," Antiviral Chemistry & Chemotherapy, (1992), pp. 157-164, 3(3) | |
| | C3 | CHAMBERLAIN, et al., "2'-Ester Prodrugs of the Varicella-Zoster Antiviral Agent, 6-Methoxypurine Arabinoside," Antiviral Chemistry & Chemotherapy, (1992), pp. 371-378, 3(6) | |
| | C4 | HARNDEN, et al., "Prodrugs of the Selective Antiherpesvirus Agent 9-[4-Hydroxy-3-(hydroxymethyl)but-1-yl]guanine (BRL 39123) with Improved Gastrointestinal Absorption Properties," J. Med. Chem., (1989), pp 1738-1743, 32 | |
| | C5 | HODGE, et al., "Selection of an Oral Prodrug (BRL 42810; Famciclovir) for the Antiherpesvirus Agent BRL 39123 [9-4-(Hydroxy-3-Hydroxymethylbut-1-yl)Guanine; Penciclovir]," Antimicrobial Agents and Chemotherapy, (1989), pp. 1765-1773, 33(10). | |
| | C6 | JONES, et al. "Di- and Triester Prodrugs of the Varicella-Zoster Antiviral Agent 6-Methoxypurine Arabinoside," J. Med. Chem, (1992), pp. 56-63, 35. | |
| | C7 | KIM, et al., "Synthesis and Evaluation of 2-Amino-9-(1,3-dihydroxy-2-propoxymethyl)-6-fluoropurine Mono- and Diesters as Potential Prodrugs of Ganciclovir," J. Med. Chem., (1999), pp. 324-328, 42. | |
| | C8 | MAAG, Hans et al., "Synthesis and Anti-HIV Activity of 4'-Azido- and 4'-Methoxynucleosides," J. Med. Chem., (1992), pp. 1440-1451, 35 | |
| | C9 | MOFFATT, J.G., "Chemical Transformations of the Sugar Moiety of Nucleosides", Nucleoside Analogues, (R. T. Walker, E. De Clercq, & F. Eckstein, eds.), (1979), pp. 71-164, Plenum Press, New York. (see p. 144) | |
| | C10 | NIELSEN, et al., "Human Peptide Transporters: Therapeutic Applications," Expert Opinion, Ther. Patents (2002), pp. 1329-1350, 12(9), Ashley Publications | |
| ▼ | C11 | PUE, et al., "Pharmacokinetics of Famciclovir in Man," Antiviral Chemistry & Chemotherapy, (1993), pp. 47-55, 4, Suppl. 1 | |
| M.C.H | C12 | RUBIO-ALIAGA, et al., "Mammalian Peptide Transporters as Targets for Drug Delivery," Trends in Pharmacological Sciences, (2002), pp. 434-440, 23(9) | |

| | | | |
|--------------------|---|-----------------|---------|
| Examiner Signature |  | Date Considered | 8/17/04 |
|--------------------|---|-----------------|---------|

I. *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

I. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.